Long-term efficacy and safety of Hizentra® in patients with primary immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials by Jolles, Stephen et al.
ORIGINAL ARTICLE
Long-Term Efficacy and Safety of Hizentra® in Patients
with Primary Immunodeficiency in Japan, Europe, and the United States:
a Review of 7 Phase 3 Trials
Stephen Jolles1 & Mikhail A. Rojavin2 & John-Philip Lawo3 & Robert Nelson Jr4 & Richard L. Wasserman5 &
Michael Borte6 & Michael A. Tortorici2 & Kohsuke Imai7 & Hirokazu Kanegane8
Received: 6 April 2018 /Accepted: 4 October 2018
# The Author(s) 2018
Abstract
Many patients with primary immunodeficiency (PID) require immunoglobulin G (IgG) replacement therapy, delivered as
intravenous IgG (IVIG) or subcutaneous IgG (SCIG). We aim to identify trends in efficacy and safety that would not be evident
in individual studies of small patient numbers. Seven open-label, Phase 3, prospective, multicenter studies of the efficacy and
safety of Hizentra® (a SCIG), conducted in Japan, Europe, and the US were summarized. Overall, 125 unique patients received
15,013 weekly infusions during a total observation period of 250.9 patient-years. Mean weekly doses of Hizentra® were 83.22–
221.3 mg/kg body weight; infusion rates per patient (total body rate) were 25.2–49.3 mL/h across studies. The rates of infections
and serious bacterial infections were 3.10 and 0.03 events per patient/year, respectively. Annualized rates of days hospitalized due
to infection, out of work/school, and prophylactic antibiotic use were 0.95, 5.14, and 36.78 per patient, respectively. For the
equivalent monthly dose, weekly Hizentra® SCIG administration resulted in expectedly-increased serum IgG trough levels in
patients switching from IVIG, and maintained levels in patients switching from previous SCIG. Adverse events (AEs) totaled
5039 (events/infusion 0.094–0.773), almost all of which were mild/moderate. Three thousand one hundred ninety-seven were
considered treatment-related, the most common of which were injection site reactions (2919 events; 0.001–0.592 AEs per
infusion). Systemic AEs were very uncommon. The results from these seven studies indicate that Hizentra® therapy was both
efficacious and well tolerated during long-term treatment. This is particularly important in patients with PID, who may require
lifelong IgG replacement therapy.
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Introduction
The majority of patients with primary immunodeficiency
(PID), including common variable immunodeficiency
(CVID) and X-linked agammaglobulinemia (XLA), require
immunoglobulin G (IgG) replacement therapy [1–3].
Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) are
two options for the delivery of this treatment [4].
SCIG and IVIG are equally effective [5, 6]; however, SCIG
does not require venous access, and is associatedwith improved
quality of life for patients [7], more stable serum IgG level
profiles [8], potential reductions in Bwear-off effect^ [9], lower
incidence of systemic adverse events (AEs) [6], and reduced
cost [10], compared with IVIG. SCIG delivery also permits the
patient flexibility with their treatment schedule, and enables
home-based self-administration for many patients [1, 7].
Hizentra® (CSL Behring, King of Prussia, PA, USA) was
the first 20% liquid IgG product approved for SCIG adminis-
tration. The high IgG concentration permits administration of
smaller volumes, while the relatively low viscosity facilitates
high infusion rates [11, 12]. Five published clinical trials pro-
vide evidence that Hizentra® is efficacious and well tolerated
by patients with PID [12–15]. Herein, we summarize results
from those trials and two additional unpublished extension
studies to further define long-term efficacy and safety in a
global context. This integrated summary sought to identify
trends in efficacy and safety that might not be evident in indi-
vidual trials of small numbers of patients, as often occurs with
clinical trials in PID.
Methods
Patients and Study Designs
Data were reviewed from seven open-label, Phase 3, prospec-
tive, multicenter studies as follows: (1) Japan (pivotal
[NCT01199705] [15], follow-up [NCT01458171], and exten-
sion [NCT01461018] studies; performed September 2010–
July 2014); (2) Europe (pivotal [NCT00542997] [13] and ex-
tension [NCT00751621] studies [14]; performed September
2007–December 2011) , and (3) the US (pivota l
[NCT00419341] [12] and extension [NCT00719680] studies
[14]; performedNovember 2006–June 2010) were included in
the analysis.
Methods used in five of these studies were published pre-
viously [12–15]. Included in Supplementary Material are pre-
viously unpublished aspects of the study design, methods, and
results including longer term follow-up results from the piv-
otal study from Japan [15].
Patients included in the analysis were those who had con-
firmed PID previously treated with IVIG at 3–4 weekly inter-
vals either for three doses (Japan pivotal study) or 3months (US
pivotal study); the European pivotal study included patients
administered IVIG at 3–4 weekly intervals or SCIG at regular
weekly intervals, both for at least 6 months. The patient ages
ranged from 2 to 75 years (Japan and US pivotal studies), 2 to
≤ 65 years (European pivotal study), and 16–65 (UK sites with-
in the European study).
Major exclusion criteria included the following: (1) newly
diagnosed PID (i.e., not having received previous IgG replace-
ment therapy); (2) serious bacterial infection (SBI) at the time of
screening or first infusion; (3) lymphoreticular malignancies in-
cluding chronic lymphocytic leukemia, non-Hodgkin’s lympho-
ma, or thymoma with immunodeficiency; (4) a positive PCR
result at screening for any of the following viral markers: human
immunodeficiency virus, hepatitis C virus, or hepatitis B virus.
The duration of each of the seven studies is shown in Fig. 1.
The Japanese pivotal study included a screening period, an
IVIG treatment period (three infusions), a 12-week SCIG
wash-in/wash-out period, and a 12-week SCIG efficacy peri-
od. The European pivotal study included a 12-week wash-in/
wash-out period followed by a 28-week efficacy period. The
US pivotal study included a 12-week wash-in/wash-out period
followed by a 12-month efficacy period. For patient disposi-
tion, see Fig. S1.
The majority of doses were administered at home follow-
ing patient self-infusion or their caregiver’s infusion technique
training. During site visits, infusions were performed under
the supervision of study site personnel. In the Japanese and
European pivotal studies, Hizentra® dosages were equivalent
to those received during their previous treatment regimen (ei-
ther IVIG or alternative SCIG). In the US pivotal study, a
conversion factor of 1.53 was used to calculate a monthly
SCIG dose bioequivalent to the previous IVIG dose. This
conversion factor was based on previous pharmacokinetic
studies that showed a dose ratio of SCIG (Hizentra®):IVIG
of 1.53 (range 1.26–1.87) led to an area under the curve
(AUC) [8] equivalent to IVIG. Subsequent pharmacometric
modeling revealed that the total systemic IgG exposure at
steady-state remains within the common equivalence range
for the AUC ratio (0.8–1.25) with a dose conversion factor
of 1.30–1.53 when switching from 4-weekly IVIG to weekly
SCIG [16]. In the Japanese and European studies, 1:1 dosing
was used, as the regulatory authorities in these areas recognize
the equivalence of serum IgG trough levels [11, 17].
In all follow-up and extension studies, the doses used
remained the same on a mg/kg basis as in the previous pivotal
or follow-up study. Doses in all studies could be adjusted if
medically indicated, or if a patient’s weight changed by more
than 5% at any time during the study period. In the US exten-
sion study, dose adjustment was permitted if an individual’s
steady-state IgG trough level resulted in a trough level ratio
(ratio of trough on Hizentra® to the last steady-state trough on
the pre-study IVIG therapy) that differed by more than 15%
from the pre-specified value of 1.29.
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Efficacy and Safety Assessments
The objectives and endpoints of each study are described in
Table S1. Efficacy endpoints included the rate of SBIs (defined
as bacterial pneumonia, bacteremia/septicemia, osteomyelitis/
septic arthritis, bacterial meningitis, or visceral abscess) [18];
the number of infection episodes (serious and non-serious); se-
rum IgG trough levels; the number of days hospitalized due to
infections; the number of days out of work, school, kindergarten,
or daycare or parental restriction of normal activities due to in-
fections (hereafter referred to as days out of work/school); and the
duration of antibiotic use for infection prophylaxis and treatment.
Safety endpoints included the type, number, rate, severity and
treatment-relatedness of any AEs per infusion and per patient,
and local tolerability of subcutaneous Hizentra® administration.
AEs were coded using the Medical Dictionary for Regulatory
Activities (MedDRA) version 14.1 in the Japanese and
European extension studies, version 12.0 in the European pivotal
study, version 11.0 in the US pivotal study, and version 13.1 in
the US extension study.
The initial US Hizentra® study procedures included injec-
tion site reaction (ISR) evaluations by the patient and the
physician, using a variety of methods and multiple mandatory
time points during and after infusion. Most ISRs in the US
pivotal study were transient, mild, expected, and spontaneous-
ly resolving, with approximately 50% of ISRs resolving with-
in 24 h post infusion. Subsequently, less stringent patient/
caregiver evaluations (at 24 h [US extension study], at 24–
72 h [European pivotal, Japan pivotal, and follow-up study],
or at an unspecified time point [European and Japan extension
studies]) were used to assess ISRs.
Pharmacokinetic Methods
A population pharmacokinetic (PK) analysis was conducted
using IgG serum concentration data from the clinical trials de-
scribed above and in Table S1. The development of the
population PK model utilized previously-published models as
the basis for this analysis [19]. Initial reference models were
based on a standard two-compartment PK model, with subcuta-
neous absorption modeled as a first-order process, and body
weight exponents on the key parameters central volume of dis-
tribution (V2) and clearance (CL). Endogenous IgG levels of
1.5 g/L and 4 g/L were tested. Covariate testing was performed
on body weight, ethnicity, and age. The model was evaluated
based on standard diagnostics.
Statistical Methods
Definitions of each data set are summarized in Table S2 using
descriptive statistics. Efficacy results were analyzed in the all-
treated (AT), intention-to-treat (ITT), modified ITT, or per-
protocol data sets, whereas safety was evaluated in the AT or
ITT populations.
Annualized rates were calculated by dividing the number
of episodes observed (y) by the total exposure days (T) and
multiplying by 365. Upper limits of 99% confidence intervals
(CIs) were calculated using the following formula, where T
and y are defined as above: (365/T) × (0.5 × χ2(0.99,2 × y + 2)).
The annualized rate of SBI was compared with the target rate
of <1.0 SBI per patient per year, as recommended by the US
Food and Drug Administration (FDA) [18].
Total serum IgG trough levels during Hizentra® therapy
were compared with those achieved during the mandatory
IVIG treatment periods by calculating the geometric mean
ratios (GMR) and respective 90% CIs.
The individual rates of AEs per infusion were calculated
for each patient by counting all AEs experienced by one pa-
tient and dividing by the total number of Hizentra® infusions
administered to this patient. Similar calculations were per-
formed for overall rates of AEs per infusion, using the total
number of AEs divided by the total number of infusions.
The analysis of the number of infections per calendar month
utilized a logistic regression model based on a Poisson
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Fig. 1 Study duration. AT all treated, ITT intention-to-treat, MITT modified intention-to-treat, PPS per protocol set
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distribution using SAS® PROC GENMOD (SAS Institute Inc.,
Cary, NC, USA). The possibility of a seasonal effect was
assessed based on pairwise differences between months. No
adjustment for multiplicity was made in the exploratory analysis
of differences between months and the level of significance was
set to 5% for each comparison. Seasonal effect was further
assessed by fitting a LOESS regression to obtain a reasonable
fit of the observed values. Based on this result, a GENMOD
model was built to test the model parameters.
Comparisons between the rates of AEs in patients receiving
an IVIG product, Privigen® (IgPro10, CSL Behring, King of
Prussia, PA, USA) and Hizentra® were performed using the
safety data from the Japanese follow-up and extension studies,
all European and US studies, and two multicenter studies of
Privigen (NCT00168025 and NCT00322556). Specific
MedDRA preferred terms for reactions typical for IgG re-
placement therapy, (injection/infusion site reactions, fatigue,
headache, nausea, vomiting, and pyrexia) were identified and
searches performed using the MedDRA data collected from
each study. Event rates per compound were calculated as total
events over the total number of infusion (14,696 for Hizentra®
and 1809 for Privigen®). The ratio of rates and its 95% CIs
were calculated as outlined in Graham et al. [20].
All analyses were carried out using SAS® software version
9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Patients
A total of 125 unique patients in the ITT/AT populations re-
ceived 15,013 weekly infusions; treatment characteristics are
presented in Table 1. Across studies, a total of 43 patients
discontinued SCIG for numerous reasons, the most common
being withdrawal of consent (n = 20), AEs (n = 12) and
Bother^ reasons, such as loss to follow-up, termination of
study site, non-compliance etc. (n = 11).
In Japan, Europe, and the US, patients were enrolled for up
to 183, 208, and 168 consecutive weeks, respectively (Table 1,
Fig. 1). The populations testing efficacy included 108 unique
patients; who were treated for a total of 91,567 days
(250.9 years). Across the PPS populations, 84 unique patients
received Hizentra® for a treatment period ≥1 year.
Baseline patient characteristics for each study are presented
in Table 2. There were 11, 23, and 10 children and adolescents
in the Japanese, European, and US pivotal studies, respective-
ly. There were six patients aged ≥65 years amongst pivotal
trials, all from the US pivotal trial.
In the Japanese and European pivotal studies, the proportion
of patients with XLAwas relatively high; therefore, male partic-
ipants outnumbered females. The Japanese pivotal study includ-
ed a female patient with a rare extremely skewedX-chromosome
inactivation leading to XLAwhose diagnosis had been previous-
ly confirmed [21]. Most patients in the US pivotal study had
CVID, and the ratio of men to women was more equal.
Study Drug Administration
Mean weekly doses of Hizentra® ranged from 83.22 mg/kg
(standard deviation [SD], 33.15) in the Japanese pivotal study
to 221.3 mg/kg (SD, 73.38) in the US extension study
(Table 1). Mean infusion rates within studies ranged from
25.2 mL/h in the Japanese pivotal study to 49.3 mL/h in the
US extension study (Table 1), while mean (SD) infusion
Table 1 Treatment characteristics
Study Japanese pivotal
(PPS)
Japanese follow-up
(PPS)
Japanese
extension (PPS)
European
pivotal (ITT)
European
extension (AT)
US pivotal
(MITT)
US extension
(ITT)
Total number of patients 21 19 17 46 40 38 21
Weeks of enrollment 24 24 135 40 168 64 104
Total SCIG infusions 504 456 2123 1794 5405 2,264a 1735
Weekly dose, mg/kg
bw, mean (SD)
83.22 (33.15) 97.56 (35.81) 90.31 (31.38) 118.7 (35.51) 115.5 (29.41) 213.2 (77.98)b 221.3 (73.38)b
Infusion rate, mL/h,
mean (SD)
25.2c (6.6) 27.1 (5.6) 27.9 (5.6) 25.1 (9.3) n.a. 39.1d (13.4) 49.3 (19.8)
Infusion duration, h,
mean (SD)
0.98c (0.50) 0.97 (0.42) 1.07 (0.49) 1.27 (0.53) n.a. 2.31 (1.20) 2.08 (1.16)
AT all treated, bw body weight, ITT intention-to-treat,MITT modified intention-to-treat, n number of patients, n.a. data not available, PPS per-protocol
set, SCIG subcutaneous immunoglobulin, SD standard deviation
a ITT population
bMean of individual patients’ median weekly doses
c During the efficacy period
dMean of individual median infusion rates
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duration ranged from 0.98 (0.50) h in the Japanese follow-up
study to 2.31 (1.20) h in the US pivotal study (Table 1).
Efficacy
Overall, there were seven SBIs in the combined studies, and the
annualized rate of SBIs in the combined studies was 0.03 (upper
99% CI limit 0.064, Table S3). There were no SBIs in the
Japanese studies, the European pivotal study, and the US pivotal
study (annualized rates 0). For the US pivotal study, this meant
that its primary objective of an annualized SBI rate of <1 per
patient was met. A total of 778 infections were reported in the
combined studies, with an annualized rate of 3.10 (upper 99%CI
limit 3.37) events per patient (Table S3). The annualized rate of
infections in individual studies ranged from 1.91 to 5.18 (Fig. 2).
There were significantly more infections starting in January,
March, October, November, and December compared with May
and July (p < 0.05). The LOESS regression revealed a smooth
parabolic curve; therefore, a generalized model with a linear and
quadratic term for calendar month was used to determine statis-
tical significance. Both terms were significant (p = 0.0014 and
p = 0.0004, respectively), indicating a significant drop in the fre-
quency of infections during the middle of the calendar year
(Fig. 3). Only one of seven SBIs started in a summer month.
The number of days hospitalized due to infection was 238 days
in the combined studies, with an annualized rate of 0.95 (upper
99% CI limit 1.10) days per patient (Table S3). The annualized
rate of days hospitalized due to infection in individual studies
ranged from 0.00 to 3.48 (Fig. 2).
In total across all studies, there were 1292 days out of
work/school rendering annualized rates of 2.06–8.00 events
per patient across individual studies (Table S3).
Overall, there were 9226 days of antibiotic treatment used for
infection prophylaxis in all seven studies combined, with an an-
nualized rate of 36.78 (upper 99%CI limit 37.68) days per patient
(Table S3). Antibiotic use was much higher in the Japanese study
compared with the European and US studies (Fig. 2).
In the Japanese, European, and US pivotal studies,
switching to weekly Hizentra® SCIG resulted in an increase
in serum IgG trough levels. Patients who received IVIG prior
to Hizentra® (including 19 patients in the European pivotal
study who received SCIG therapy other than Hizentra®) had
median (range) baseline serum IgG trough levels of 5.90
(4.67–10.01), 6.48 (5.26–11.71), and 10.47 (6.54–19.0) g/L,
respectively. Median (range) serum IgG trough levels at
follow-up studies were 6.64 (5.20–10.43), 8.09 (5.2–11.2),
Table 2 Baseline patient characteristics
Study Japanese
pivotal (AT)
Japanese
follow-up (AT)
Japanese
extension (AT)
European
pivotal (AT)
European
extension (AT)
US pivotal
(ITT)
US extension
(AT)
Total number of patients 25 23 22 51 40 49 21
Gender, n (%)
Female 9 (36.0) 9 (39.1) 9 (40.9) 16 (31.4) 12 (30.0) 27 (55.1) 15 (71.4)
Male 16 (64.0) 14 (60.9) 13 (59.1) 35 (68.6) 28 (70.0) 22 (44.9) 6 (28.6)
Age (years)
Mean (SD) 20.6 (13.32) 20.8 (13.68) 21.6 (14.0) 22.6 (16.0) 21.6 (15.3) 34.4 (20.1) 42.4 (18.5)
Median (range) 18.0 (3–58) 17.0 (4–58) 18.5 (4–59) 18.0 (3–60) 16.0 (4–52) 32.0 (5–72) 42.0 (11–69)
Age group, n (%)a
2–11 years 7 (28.0) 6 (26.1) 5 (22.7) 18 (35.3) 15 (37.5) 3 (6.1) 1 (4.8)
12–15 yearsb 4 (16.0) 5 (21.7) 5 (22.7) 5 (9.8) 4 (10.0) 7 (14.3) 1 (4.8)
16–64 yearsc 14 (56.0) 12 (52.2) 12 (54.5) 28 (54.9) 21 (52.5) 33 (67.3) 16 (76.2)
≥65 years 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (12.2) 3 (14.3)
Body mass index (kg/m2)
Mean (SD) 18.9 (3.68) 18.9 (3.19) 19.2 (3.1) 20.6 (4.7) 20.5 (4.7) n.a. 26.4 (6.5)
Median (range) 18.2 (15–33) 18.4 (15–30) 18.8 (15–29) 20.2 (12–32) 20.6 (14–31) n.a. 26.2 (18–43)
Primary disease, n (%)
CVID 10 (40.0) 10 (43.5) 10 (45.5) 30 (58.8) 23 (57.5) 46 (93.9) 21 (100.0)
XLA 13 (52.0) 11 (47.8) 10 (45.5) 20 (39.2) 16 (40.0) 3 (6.1) 0 (0.0)
ARAG 1 (4.0) 1 (4.4) 1 (4.5) 1 (1.9) 1 (2.5) 0 (0.0) 0 (0.0)
ARAG autosomal recessive agammaglobulinemia, ATall treated,CVID common variable immune deficiency, FAS full analysis set, ITT intention-to-treat,
n number of patients, n.a. data not available, SD standard deviation, XLA X-linked agammaglobulinemia.
a There were no patients <2 years of age
b In the Japanese pivotal, follow-up, and extension studies, this group included patients aged 12–16 years
c In the Japanese pivotal, follow-up, and extension studies, this group included patients aged 17–64 years
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and 11.43 (7.24–22.04) g/L in the Japanese, European, and
US pivotal studies, respectively with dose adjustment in the
US study (Table 3). Those who switched to Hizentra® SCIG
from a previous SCIG hadmedian (range) IgG trough levels in
the European pivotal study of 8.73 (5.22–10.15) g/L on
Hizentra® vs 8.57 (5.36–10.30) on previous SCIG.
In the European pivotal study, the primary objective of
sustained serum IgG levels withHizentra® similar to the patients’
previous IgG treatment was clearly met. The mean of individual
median IgG trough values with Hizentra® treatment was slightly
higher in patientswith CVID (8.37 g/L during infusions 12 to 17)
than in patients with XLA (7.61 g/L during infusions 12 to 17);
however, the increase was comparable (6.9% in CVID compared
to 8.7% in XLA). The primary objective of the Japanese pivotal
study was also met, as the GMR of serum IgG trough levels was
similar to those of the preceding IVIG treatment period (GMR=
1.09; 90%CI 1.06–1.14). All three pivotal studies, therefore, met
their respective primary objectives.
There were no clinically relevant differences between me-
dian serum IgG trough concentrations at baseline and during
SCIG maintenance dosing in the follow-up and extension
studies (Table 3).
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Pharmacokinetics
The final structural population PK (pharmacometric) model
was a two-compartment model with inter-individual variabil-
ity on CL and V2 on all patients. The median values of all
non-covariate parameters from bootstrap resampling were
consistent with the original population PK estimates
(Table S4). The effect of body weight on CL and V2 was
within the 90% CI but was more variable, and the CIs for
these parameters were relatively wide (Table S4).
Analysis of pooled data revealed no differences in IgG
metabolism between ethnic groups despite the numerically
different results. The effect of the Japanese population was
also tested in various sensitivity models, results from which
showed that there was no significant race-related covariate
effect from the inclusion of Japanese patients (Fig. S2).
After adjustment for average body weight, major PK variables
affecting IgG half-life, such as CL and V2, were the same in
the Caucasian and Asian patient populations (unpublished
data).
Safety
There were 5039 AEs in total across all studies. Overall, there
were no relevant differences in the frequency of AEs between
the different age groups receiving Hizentra® in any of the
studies, and there was no increase in the rate of AEs with
increasing age, as might be expected. The rates of AEs per
infusion were also similar in male and female patients. The
incidence of patients with AEs at least possibly related to the
study medication in the European pivotal study appeared
higher in patients with CVID compared with patients with
XLA (23 [76.7%] vs. 8 [40.0%], respectively).
Events per infusion ranged from 0.094 in the European
extension study to 0.773 in the US pivotal study (Fig. 4a).
While most patients experienced ≥1 AE, most were
mild/moderate. There was a single reaction that required infu-
sion interruption during treatment.
In total, 3197 treatment-related AEs were reported (0.003–
0.634 AEs per infusion in the combined studies; Table S5). As
expected for subcutaneous administration, the most common
treatment-related AEs were ISRs (2919 events; 0.001–0.592
AEs per infusion in the combined studies; Table S5). The rate
of ISRs was variable amongst the studies, a phenomenon that
may reflect the differences in assessment.
Systemic AEs were uncommon. Of 45 serious AEs (SAEs)
reported (0.001–0.004 SAEs per infusion in the combined
studies; Fig. 4b), two were considered possibly related to the
study medication (one case of encephalitis in the Japanese
follow-up study and one case of asthma in the Japanese ex-
tension study); however, viral infection was considered a plau-
sible alternative explanation for the episode of encephalitis. In
the European extension study, one patient with a known
ongoing history of recurrent severe pneumonia developed an
acute exacerbation and subsequently died of respiratory fail-
ure. This death was thought to be related to underlying disease
and not to the study medication.
The incidence of AEs leading to discontinuation was low in
all studies. No patients in the Japanese pivotal study and one
patient each in the Japanese follow-up study (encephalitis) and
Japanese extension study (local ISRs) discontinued the study
due to AEs. In the European studies, 6 patients (11.8%) in the
pivotal study discontinued due to AEs (at least possibly relat-
ed to study drug in 3 patients) and 1 patient died (due to AE
unrelated to study drug) in the extension study. In the US
studies, 2 patients (4.1%) in the pivotal study discontinued
due to AEs (one of which was deemed at least possibly related
to study drug), and 1 patient (4.8%) in the US extension study
discontinued due to an AE, which was not considered related
to study drug.
Comparison of Privigen® and Hizentra®
ISRs were more common with Hizentra® than with Privigen®
(ratio 90.8; 95% CI 35.27–233.51; Table S6), although only
occurring with a rate of approximately 0.2 per infusion.
However, systemic AEs such as fatigue, headache, vomiting,
nausea, and pyrexia were more common with Privigen®
(≤0.22 events/infusion) than with Hizentra® (≤0.00915
events/infusion). Ratios were ≤0.0981, indicating an approxi-
mately 10-fold lower incidence of these events in patients
receiving Hizentra®. These results underline the expected out-
come that ISRs are more common with SCIG than IVIG,
while systemic reactions are, conversely, less common with
SCIG than with IVIG.
Discussion
This review of seven Phase 3 clinical trials in 125 patients who
received 15,013 weekly infusions for a total observation peri-
od of 250.9 patient years supports that SCIG Hizentra® ad-
ministration as a treatment is effective against infections, par-
ticularly SBIs, in a broad age range of patients with PID.
Weekly SCIG Hizentra® administration increased serum
IgG trough levels compared with equivalent monthly doses
of IVIG.Maintenance serum IgG trough levels were similar to
those associated with previous SCIG therapy. These results
are in agreement with the known advantages of SCIG com-
pared to IVIG and confirm the well-recognized increase in
trough IgG following a dose-equivalent switch from IVIG to
SCIG [1, 5]. In addition, a previous pharmacometric modeling
and simulation study, which partly used data from the US and
European pivotal trials, showed that weekly or biweekly
SCIG dosing would produce serum IgG levels within 10%
of those achieved with 4-weekly IVIG dosing [19].
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Furthermore, pharmacometric analysis showed that a range of
subcutaneous dosing schedules (from daily to biweekly) for
the same total equivalent weekly dose that provide similar
serum IgG levels [22] can be implemented.
Annualized infection rates, SBIs, and days spent in hospital
due to infection were low, and compared favorably to findings
of previous studies that examined the effects of other SCIG
therapies in PID [23]. The annualized SBI rates captured in
the combined European and US extension studies were well
below the accepted US FDA and European Medicines
Agency threshold of 1 SBI per patient year [14]. No patients
were reported to have SBIs in the US pivotal study, EU pivotal
study, or any of the Japanese studies. The highest annualized
rate of SBIs was only 0.06 infections per patient per year (ob-
served in the US extension study) which is lower than the
previously-reported annualized rate of 0.08 with IVIG for the
treatment of PID [24]. Since patients who receive adequate IgG
replacement therapy may still experience occasional serious
infections, especially in those with pre-existing conditions such
as bronchiectasis, it is expected that some SBIs will be captured
within the time frame of these extension studies, and formed
part of the purpose of analysis of this large dataset [25, 26].
The majority of patients, including those who experienced a
SBI, had serum IgG trough levels within the normal range.
Also, clear seasonal patterns of infection frequency and severity
were observed in these patients. This suggests that increased
monitoring during the months fromOctober to February, which
are traditionally associated with higher infection risk, may be
advisable for patients with PID. Further research is needed to
evaluate if seasonally-optimized SCIG doses and/or targeted
use of prophylactic antibiotics during this period would be ben-
eficial. It may also be that IgG replacement therapy does not
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offer patient as much protection from upper airway viral infec-
tions as it does protection from pneumonia [27].
The rates of hospitalization were higher in the European stud-
ies comparedwith the Japanese andUS studies. However, results
from the European studies were disproportionally affected by the
experience of a single 5-year-old female patient who experienced
three SAEs that resulted in 71 school days missed and 63 days
spent in hospital [13]. Excluding this patient, the number of days
hospitalized decreased from3.48 to 0.95 days per patient per year
[13]. Another possible factor concerning the interpretation of
these findings is that the threshold for hospitalization and dura-
tion of in-hospital staymay be lower inmanyEuropean countries
compared with the US and other countries as a function of dif-
fering practice standards.
SCIG has previously been shown to be associated with a
lower rate of AEs than IVIG. Several open-label prospective
studies in the US and Europe have reported a zero incidence of
SAEs related to SCIG [28–30]. In previously-published stud-
ies, the incidence of SAEs related to IVIG was reported to
range 9–29% [31–33]. The present analysis showed a similar
incidence of SAEs, ranging from 4% in Japanese pivotal study
to 35% in European extension study. SAEs reported were
unrelated to study drug across all studies with the exception
of 1 SAE each in the Japanese follow-up study (encephalitis)
and extension study (asthma). However, it is difficult to draw
meaningful conclusions due to potential differences in the
measurement and recording of AEs, patient demographic
characteristics, and treatment parameters.
In line with previous studies, Hizentra® was well tolerated.
AEs were predominately mild or moderate, and mostly ISRs.
The safety profile of Hizentra® was similar to that of other
subcutaneous IgG replacement therapies, in terms of the type,
frequency, and treatment-relatedness of AEs [34, 35]. The
comparison of AEs observed in patients receiving IVIG and
SCIG included in this analysis confirms the expected outcome
that ISRs are more common, while systemic reactions are less
common, with SCIG than IVIG.
Interestingly, the ISR rates differed widely across the seven
trials, as did the assessment methods, time points, and scales for
reporting ISRs. The rate of ISRs in the US studies [12, 14]
appeared higher in comparison with the Japanese and
European studies. In this regard, the US pivotal study was the
first clinical trial using Hizentra®, and ISRs were comprehen-
sively evaluated by both the patient and the investigator, using a
variety of methods at multiple mandatory time points and with
leading questions during and after infusion [12]. Most ISRs
were mild and transient, did not require treatment, and were
otherwise felt to be expected consequences of simply infusing
fluid into the subcutaneous tissue. These findings lead to adjust-
ments to less stringent evaluation criteria in subsequent studies
with Hizentra® and other SCIGs [13–15, 34, 35]. The reported
incidences and rates of infusion site AEs in the European and
Japanese studies were also similar to those reported in studies
using an alternative, recently-licensed, 20% IgG therapy, includ-
ing those reported in US patients [36, 37]. In the European
pivotal study, the rate of temporally-associated AEs was similar
for all starting infusion rates (0.142 in the <15 mL/h group,
0.172 in the 15–25 mL/h group, and 0.191 in the >25 mL/h
group). Across US studies, no trends in overall AE rates per
infusion rate were reported, with the exception of a lower AE
rate of 0.686 in the group with the highest infusion rates of
>25 mL/h, compared with a higher AE rate of 0.887 with the
lower infusion rates of 15–25 mL/h in the US pivotal study,
although these differences were not compared statistically. In
the Japanese pivotal study, the overall AE rate was 0.362 for
patients receiving SCIG at a rate of 15–25 mL/h and 0.286 for
those at >25 mL/h. In the Japanese follow-up study, the rate of
all temporally-associated AEs for infusions of 15–25 mL/h was
0.150, compared with 0.298 for >25 mL/h, however the limited
number of patients reporting a high number of AEs in either
infusion rate group and the uneven distribution of AEs means
that these results should be interpreted with caution. No trends
were observed in the Japanese extension study. The lack of
comparative, head-to-head trials between available 20% IgG
replacement products requires thoughtful consideration of dif-
ferences in reporting methodology that may contribute signifi-
cantly to reported differences in adverse reactions rates. These
findings also emphasize that standardization of definitions and
timing of infusion site AE capture amongst in different countries
and different companies could be beneficial for future studies.
The stability of serum IgG concentrations during SCIG
maintenance phases (i.e., during the Japanese follow-up study
and the Japanese, European, and US extension studies) sug-
gests that adherence to effective dosing and delivery was ex-
cellent in these cohorts. Furthermore, the low numbers of pa-
tients discontinuing treatment suggested that Hizentra® SCIG
was also well tolerated.
There were some differences between the Japanese,
European, and US studies. These include distribution of pri-
mary endpoints, study designs (mandatory IVIG treatment
period in the Japanese pivotal study only), study length, de-
mographics, and SCIG dose (calculated using a conversion
factor of 1.53 in the US pivotal study vs an equivalent dose
to previous IVIG therapy in the European and Japanese piv-
otal studies). Furthermore, the use of prophylactic antibiotics
appeared higher in the Japanese studies, most likely as a result
of local prescribing practices.
Conclusions
Long-term tolerability of IgG replacement therapy in PID is
an important consideration, as patients often require IgG
throughout life. The results of these studies indicate that re-
peated, self-administered SCIG Hizentra® therapy up to
4 years is efficacious and well tolerated.
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